Form 4: Janux Therapeutics CEO Reports Stock Transactions

Janux Therapeutics CEO David Alan Campbell reported the sale of shares for tax obligations and the grant of new restricted stock units and stock options.

Summary

• David Alan Campbell, President and CEO of Janux Therapeutics, Inc. (JANX), reported transactions involving the company's common stock and derivative securities.
• On January 2, 2026, 8,072 shares of common stock were sold at a price of $13.73 per share to cover tax withholding obligations associated with the vesting of restricted stock units.
• Following this sale, Campbell's direct beneficial ownership of common stock was 284,982 shares.
• On the same date, Campbell was granted 96,600 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock, with a transaction price of $0.
• These RSUs will vest in four equal annual installments, commencing on January 1, 2027.
• After the RSU grant, Campbell's direct beneficial ownership of common stock increased to 381,582 shares.
• Additionally, Campbell was granted stock options to buy 338,100 shares at an exercise price of $13.65 per share, with a transaction price of $0.
• 25% of the shares subject to the option will vest on January 1, 2027, with the remaining balance vesting in equal monthly installments over a three-year period thereafter.
• The expiration date for these stock options is January 1, 2036.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to significant equity grants (RSUs and stock options) to the CEO, which typically align management's interests with shareholders. The sale of shares was for tax purposes, a routine event, and does not indicate negative sentiment.

Positives

• The grant of 96,600 restricted stock units (RSUs) and 338,100 stock options aligns the CEO's long-term incentives with shareholder interests.
• The new equity grants demonstrate continued commitment and confidence from the CEO in the company's future performance.

Negatives

• A sale of 8,072 shares of common stock occurred, although it was explicitly stated to cover tax withholding obligations, which is a routine event for vesting equity.

Future Outlook

The vesting schedules for the granted restricted stock units and stock options extend into future years, indicating a long-term incentive structure for the CEO. RSUs will vest in four equal annual installments starting January 1, 2027, and stock options will vest 25% on January 1, 2027, with the remainder over three years.

Industry Context

Executive compensation packages frequently include equity grants such as restricted stock units and stock options to incentivize long-term performance and align management interests with those of shareholders. The reported transactions are typical for an executive receiving performance-based compensation.

Stakeholder Impact

• Shareholders: The significant grant of equity to the CEO enhances alignment between executive compensation and shareholder value creation, potentially fostering long-term growth and performance.

Next Steps

• Vesting of 25% of the granted stock options on January 1, 2027.
• First annual installment vesting of restricted stock units (RSUs) on January 1, 2027.
• Subsequent monthly vesting of stock options over a three-year period following January 1, 2027.
• Subsequent annual vesting of RSUs over three additional years following January 1, 2027.

Key Dates

Keywords

Janux Therapeutics, JANX, Form 4, Insider Transaction, David Alan Campbell, CEO, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership